Drug Trial Radar · NCT05524545
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Nov 2, 2022
Primary completion
Jun 27, 2025
Study completion Jun 27, 2025
Sponsor
- Lead sponsor
- ALX Oncology Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
Conditions
- Bladder Cancer
- Urothelial Carcinoma
Interventions
EvorpaceptDrug
Fusion protein that blocks CD47-SIRPalpha pathway
Enfortumab VedotinDrug
Nectin-4 directed antibody and microtubule inhibitor conjugate
Primary outcomes
What the sponsor says the trial is designed to measure.
- First Cycle Dose limiting toxicities (DLTs)Time frame: Up to 28 days
- Adverse Events (AEs) as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v. 5.0)), timing, seriousness, and relationship to study therapyTime frame: Up to 24 months
- Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: Up to 15 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Moffitt Cancer Center
Tampa, Florida
Massachusett's General
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center
New York, New York
University of North Carolina
Chapel Hill, North Carolina
Oregon Health & Science University
Portland, Oregon
West Clinic
Germantown, Tennessee
UT Southwestern
Dallas, Texas
Seattle Cancer Care Alliance
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.